Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Description
Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatment for cancers, atherosclerosis, and infectious diseases. The company was founded on October 11, 2000 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.1 - 0.7
Trade Value (12mth)
AU$3,068.00
1 week
-6.9%
1 month
-43.75%
YTD
-50.46%
1 year
-73%
All time high
55.25
EPS 3 yr Growth
225.90%
EBITDA Margin
-131.60%
Operating Cashflow
-$2m
Free Cash Flow Return
-14.60%
ROIC
-34.30%
Interest Coverage
N/A
Quick Ratio
2.10
Shares on Issue (Fully Dilluted)
64m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
31 January 25 |
Activities Report and Appendix 4C
×
Activities Report and Appendix 4C |
23 January 25 |
Application for quotation of securities - IVX
×
Application for quotation of securities - IVX |
23 January 25 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
14 January 25 |
Notification regarding unquoted securities - IVX
×
Notification regarding unquoted securities - IVX |
02 January 25 |
Application for quotation of securities - IVX
×
Application for quotation of securities - IVX |
02 January 25 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
16 December 24 |
Prof Rob Ramsay from Peter Mac Appointed Scientific Advisor
×
Prof Rob Ramsay from Peter Mac Appointed Scientific Advisor |
16 December 24 |
Application for quotation of securities - IVX
×
Application for quotation of securities - IVX |
16 December 24 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
11 December 24 |
Notification regarding unquoted securities - IVX
×
Notification regarding unquoted securities - IVX |
11 December 24 |
Change of Director's Interest Notice- Thian Chew
×
Change of Director's Interest Notice- Thian Chew |
11 December 24 |
Change of Director's Interest Notice - Alan Yamashita
×
Change of Director's Interest Notice - Alan Yamashita |
11 December 24 |
Change of Director's Interest Notice - Alistair Bennallack
×
Change of Director's Interest Notice - Alistair Bennallack |
03 December 24 |
Invion Doses First Patient in Phase I/II Skin Cancer Trial
×
Invion Doses First Patient in Phase I/II Skin Cancer Trial |
28 November 24 |
Completion of Securities Consolidation
×
Completion of Securities Consolidation |
27 November 24 |
Notification regarding unquoted securities - IVX
×
Notification regarding unquoted securities - IVX |
25 November 24 |
Application for quotation of securities - IVX
×
Application for quotation of securities - IVX |
25 November 24 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
14 November 24 |
AGM Presentation
×
AGM Presentation |
14 November 24 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
28 October 24 |
Activities Report and Appendix 4C
×
Activities Report and Appendix 4C |
28 October 24 |
Change of Company Secretary
×
Change of Company Secretary |
23 October 24 |
Application for quotation of securities - IVX
×
Application for quotation of securities - IVX |
23 October 24 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
22 October 24 |
Notification of cessation of securities - IVX
×
Notification of cessation of securities - IVX |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.